Impact of Combinatorial Immunotherapies in Breast Cancer: a Systematic Review and Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 31

PMID 39478857

Authors

Sandeep Sisodiya

Vishakha Kasherwal

Jyoti Rani

Neetu Mishra

Sandeep Kumar

Asiya Khan

Mehreen Aftab

Shagufta

Payal Singh

Ekta Gupta

Pranay Tanwar

Showket Hussain

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer has the highest mortality rate among all cancers affecting females worldwide. Several new effective therapeutic strategies are being developed to minimize the number of breast cancer-related deaths and improve the quality of life of breast cancer patients. However, resistance to conventional therapies in breast cancer patients remains a challenge which could be due to several reasons, including changes in the tumor microenvironment. Attention is being diverted towards minimizing the resistance, toxicity, and improving the affordability of therapeutics for better breast cancer management. This includes personalized medicine, target-specific drug delivery systems, combinational therapies and artificial intelligence based screening and disease prediction. Nowadays, researchers and clinicians are also exploring the use of combinatorial immunotherapies in breast cancer patients, which have shown encouraging results in terms of improved survival outcomes. This study attempts to analyze the role of combinational immunotherapies in breast cancer patients, and offer insights into their effectiveness in breast cancer management.

Methodology: We conducted a systematic review and meta-analysis for which we selected the randomized clinical trials (RCTs) focused on completed Phase I/II/III/IV clinical trials investigating combination immunotherapies for breast cancer. The analysis aimed to assess the efficacy of combination therapies in comparison to mono-therapies, focusing on overall survival (OS), and progression-free survival (PFS).

Results: We observed that, combination immunotherapies significantly (P<0.05) improved OS as compared to single-drug therapies in the Phase I with overall Risk ratio (RR) of 16.17 (CI 2.23,117.50), Phase II with an overall RR of 19.19 (CI 11.76,31.30) and for phase III overall RR 22.27 (CI 13.60,36.37). In the case of PFS, it was significant with RR: 12.35 (CI 2.14, 71.26) in Phase I RR 6.10 (CI 4.31, 8.64) in phase II, RR 8.95 (CI 6.09, 13.16) in phase III and RR 14.82 (CI 6.49, 33.82) in Phase IV of clinical trials.

Conclusion: The observed improvements in overall survival and progression-free survival suggest that combination immunotherapies could serve as a better approach to breast cancer management.

References

Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J . Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:562315. PMC: 8085334. DOI: 10.3389/fonc.2021.562315. View

Yang Q, Ciebiera M, Bariani M, Ali M, Elkafas H, Boyer T . Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2021; 43(4):678-719. PMC: 9277653. DOI: 10.1210/endrev/bnab039. View

Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula S, Mistriotis P, Avila L . Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics. Front Immunol. 2024; 15:1302587. PMC: 10963559. DOI: 10.3389/fimmu.2024.1302587. View

Bashraheel S, Domling A, Goda S . Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother. 2020; 125:110009. DOI: 10.1016/j.biopha.2020.110009. View

Perez-Herrero E, Fernandez-Medarde A . Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015; 93:52-79. DOI: 10.1016/j.ejpb.2015.03.018. View

Guedan S, Ruella M, June C . Emerging Cellular Therapies for Cancer. Annu Rev Immunol. 2018; 37:145-171. PMC: 7399614. DOI: 10.1146/annurev-immunol-042718-041407. View

Subhan M, Parveen F, Shah H, Yalamarty S, Ataide J, Torchilin V . Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers (Basel). 2023; 15(8). PMC: 10137302. DOI: 10.3390/cancers15082204. View

Igarashi Y, Sasada T . Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. J Immunol Res. 2020; 2020:5825401. PMC: 7685825. DOI: 10.1155/2020/5825401. View

Nazir S, Kumar R, Dil-Afroze , Rasool I, Bondhopadhyay B, Singh A . Differential expression of Ets-1 in breast cancer among North Indian population. J Cell Biochem. 2019; 120(9):14552-14561. DOI: 10.1002/jcb.28716. View

10.

Janani M, Poorkhani A, Amiriani T, Donyadideh G, Ahmadi F, Jorjanisorkhankalateh Y . Association of future cancer metastases with fibroblast activation protein-α: a systematic review and meta-analysis. Front Oncol. 2024; 14:1339050. PMC: 11094201. DOI: 10.3389/fonc.2024.1339050. View

11.

Fulgenzi C, DAlessio A, Airoldi C, Scotti L, Demirtas C, Gennari A . Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. Eur J Cancer. 2022; 174:57-67. DOI: 10.1016/j.ejca.2022.06.058. View

12.

Latif F, Bint Abdul Jabbar H, Malik H, Sadaf H, Sarfraz A, Sarfraz Z . Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Expert Rev Anticancer Ther. 2021; 22(2):229-235. DOI: 10.1080/14737140.2022.2023011. View

13.

Sisodiya S, Kasherwal V, Khan A, Roy B, Goel A, Kumar S . Liquid Biopsies: Emerging role and clinical applications in solid tumours. Transl Oncol. 2023; 35:101716. PMC: 10285278. DOI: 10.1016/j.tranon.2023.101716. View

14.

Rosen V, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk V . Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer. Int J Gynecol Cancer. 2017; 27(6):1237-1246. PMC: 5499964. DOI: 10.1097/IGC.0000000000001000. View

15.

Murciano-Goroff Y, Betof Warner A, Wolchok J . The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020; 30(6):507-519. PMC: 7264181. DOI: 10.1038/s41422-020-0337-2. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

17.

Falci S, Marques L . CONSORT: when and how to use it. Dental Press J Orthod. 2015; 20(3):13-5. PMC: 4520133. DOI: 10.1590/2176-9451.20.3.013-015.ebo. View

18.

Rezayatmand H, Razmkhah M, Razeghian-Jahromi I . Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells. Stem Cell Res Ther. 2022; 13(1):181. PMC: 9066908. DOI: 10.1186/s13287-022-02856-6. View

19.

Bondhopadhyay B, Sisodiya S, Chikara A, Khan A, Tanwar P, Afroze D . Cancer immunotherapy: a promising dawn in cancer research. Am J Blood Res. 2021; 10(6):375-385. PMC: 7811907. View

20.

Halder J, Pradhan D, Kar B, Ghosh G, Rath G . Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine. 2021; 40:102494. DOI: 10.1016/j.nano.2021.102494. View